Community/Retail

The study results also determined that those who were previously vaccinated against smallpox had a 2.7 times higher immune response than those who were not previously vaccinated.

Sleep duration is positively associated with quality of life in adolescents.

Real-world data can help resolve access barriers by providing a highly detailed view into the barriers that impact specific patient populations.

The new understanding of immune cells could not only contribute to the development of lung disease treatments, but treatments for other organ systems as well.

True patient centricity treats the whole patient and places an emphasis on broader patient engagement and satisfaction.

Although we have made strides in adopting technology to combat diversion, the uptake of advanced technology is slow and steady.

Health coaches supporting remote pharmacist services can improve diabetes disparities.

From newsworthy moments to groundbreaking research, these were the most-read pediatrics-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most watched videos on Pharmacy Focus in 2023.

From newsworthy moments to groundbreaking research, these were the most-read coronavirus-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most listened-to podcasts on Pharmacy Focus in 2023.

From newsworthy moments to groundbreaking research, these were the most-read reimbursement-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read pneumococcal-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read cardiovascular-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read pharmacy technician-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read biosimilar-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read Alzheimer disease-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read student-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read respiratory syncytial virus-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read community pharmacy-related articles from Pharmacy Times in 2023.

With gastrointestinal-based adverse effectss for rivastigmine and other cholinesterase inhibitors, a weight of <50 and <55 kg respectively leads to an increased risk for toxicities.

The drug is the first medicine to be approved for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis that can be self-administered.

Families that reported a lower income before the pandemic were more likely to experience hardships if headed by an adult with COVID-19 illness.

One could also argue that the Great Resignation is an era for a great realignment. During lockdown, many individuals took the time to realign their priorities.

The SHARE model from the CDC involves personalizing recommendations for patients and their needs, addressing any concerns they may have, and explaining the risks of remaining unvaccinated.

This latest revision introduces a new set of drug criteria, refines the existing ones, and enhances the overall formatting to ensure increased ease of use and clarity for its recommendations.

Tune in to this episode of the Independent Rx Forum for a comprehensive update on legal developments and insightful discussions on class action lawsuits and regulatory guidelines from the National Community Pharmacists Association.

Amid pharmacy strikes and ongoing challenges, technicians can identify new opportunities for growth

The biosimilars landscape is set to witness significant growth, particularly in therapeutic areas like ophthalmology and immunology, with a focus on blockbuster biologics like Humira, Stelara, and Eylea.

The cost of defending license matters and malpractice claim costs have increased over a 5-year period (2017-2022).